These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2950240)

  • 1. The immunosuppressive activity of C1q degradation peptides.
    Ninnemann JL; Ozkan AN
    J Trauma; 1987 Feb; 27(2):119-22. PubMed ID: 2950240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of in vitro lymphocyte and neutrophil responses by a low molecular weight suppressor active peptide from burn-patient sera.
    Ozkan AN; Ninnemann JL
    J Clin Immunol; 1985 May; 5(3):172-9. PubMed ID: 3159747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of immune complex levels--with special reference to C1q and the anti-antibody method].
    Kasukawa R
    Rinsho Byori; 1986 Oct; Spec No 69():35-44. PubMed ID: 3543438
    [No Abstract]   [Full Text] [Related]  

  • 4. [Complement subcomponent C1q in rheumatic diseases].
    Yonemasu K; Sasaki T
    Ryumachi; 1986 Aug; 26(4):299-311. PubMed ID: 3551118
    [No Abstract]   [Full Text] [Related]  

  • 5. Definition of a burn injury-induced immunosuppressive serum component.
    Ninnemann JL; Ozkan AN
    J Trauma; 1985 Feb; 25(2):113-7. PubMed ID: 3973938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and characterization of the 1q subcomponent of canine complement and its use in the 125I-C1q binding assay for detection of immune complexes.
    Wu CC; Bey RF; Loken KI
    Am J Vet Res; 1988 Jun; 49(6):865-9. PubMed ID: 3135770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement subcomponent C1q in various strains of mice. Its serum content correlates with that of immunoglobulin G.
    Yonemasu K; Sasaki T; Hashimoto H; Tsukao N
    Int Arch Allergy Appl Immunol; 1988; 86(1):97-101. PubMed ID: 3259550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ELISA technique for the measurement of C1q in cerebrospinal fluid.
    Delamarche C; Berger F; Pouplard A; Emile J
    J Immunol Methods; 1988 Nov; 114(1-2):101-6. PubMed ID: 3141513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1q component of complement binds to fibrinogen and fibrin.
    Entwistle RA; Furcht LT
    Biochemistry; 1988 Jan; 27(1):507-12. PubMed ID: 3258162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activity of total complement and concentration of its components C1q, C3, C4 and C1-inactivator in cancer].
    Matoses Cuquerella S; O'Connor Miquel C; Lluch Hernández AM; García-Conde Bru J
    Med Clin (Barc); 1988 Dec; 91(20):769-74. PubMed ID: 3266280
    [No Abstract]   [Full Text] [Related]  

  • 11. Subunit interactions in the first component of complement, C1.
    Lakatos S
    Biochem Biophys Res Commun; 1987 Dec; 149(2):378-84. PubMed ID: 2827640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum C1q level does not predict joint erosion in early rheumatoid arthritis.
    Möttönen T; Hannonen P; Rautiainen J; Jokinen I; Oka M; Arvilommi H
    Arthritis Rheum; 1989 Apr; 32(4):511-2. PubMed ID: 2784969
    [No Abstract]   [Full Text] [Related]  

  • 14. A method for serum C1q based on its hydroxyproline content.
    Rosano CL; Braun CB; Hurwitz C
    Clin Chem; 1987 Mar; 33(3):398-400. PubMed ID: 3102124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 and C1q complement deposits in the membranous labyrinth of patients with Ménière's disease.
    Häusler R; Arnold W; Schifferli J
    Adv Otorhinolaryngol; 1988; 42():116-22. PubMed ID: 3063094
    [No Abstract]   [Full Text] [Related]  

  • 16. [The role of the immunoglobin G "hinge" region in heat aggregation and activation of complex-formation].
    Khristoforov VS; Persanov VM; Sukhomudrenko AG; Abramov VM; Zav'ialov VP
    Biofizika; 1987; 32(1):32-6. PubMed ID: 3493035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal antibody to C1q which appears to interact with C1r2C1s2-binding site.
    Hsiung L; Dodds AW; Mason DW; Reid KB
    FEBS Lett; 1988 Feb; 229(1):21-4. PubMed ID: 2831088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q.
    Uwatoko S; Mannik M
    J Clin Invest; 1988 Sep; 82(3):816-24. PubMed ID: 3262124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages.
    Bobak DA; Gaither TA; Frank MM; Tenner AJ
    J Immunol; 1987 Feb; 138(4):1150-6. PubMed ID: 3492544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of complement activation in ischemic myocardium: identification of specific molecules of mitochondrial origin that bind human C1q and fix complement.
    Kagiyama A; Savage HE; Michael LH; Hanson G; Entman ML; Rossen RD
    Circ Res; 1989 Mar; 64(3):607-15. PubMed ID: 2783892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.